Plain-English translation of NCT07758270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing how , a new type of MS medication, affects inflammation deep inside the brain and spinal cord. Researchers will use advanced imaging scans and blood tests to see whether this medication reduces the immune activity that may be driving MS progression, even when visible relapses are controlled. The goal is to understand whether these test results can help predict how well the medication will work for each person.
MS involves ongoing inflammation in the brain and spinal cord that can worsen the disease even when relapses seem to be controlled. Doctors don't yet fully understand how this medication affects that deeper inflammation, or how to measure whether it's working at the cellular level. This study aims to fill that gap by finding measurable signs—called biomarkers—that could help doctors monitor treatment response and predict long-term outcomes.
You likely qualify if…
You likely don't qualify if…
Participants will undergo advanced brain imaging scans (PET and MRI), have blood and cerebrospinal fluid samples collected, and complete standard MS assessments over the course of the study. You will either continue with (if you were already taking it) or switch to it from ocrelizumab, as part of a parent study called RESHAPE-MS. The imaging and testing will help researchers track how the medication affects inflammation markers in your brain and blood over time.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States